A patent is a document, issued, upon application, by a government office (or a regional office acting for several countries), which describes an invention and creates a legal situation in which the patented invention can normally only be exploited (manufactured, used, sold, imported) with the authorization of the holder of the patent. ‘Invention’ means a solution to a specific problem in the field of technology. An invention may relate to a product or a process. The protection conferred by the patent is limited in time, generally 20 years. In a number of countries, inventions are also protectable through registration of a ‘utility model’ or ‘short-term patent’.
It’s this time of the year again – merry Christmas, happy holidays and/or best wishes for whatever you are celebrating next week. This year’s Christmas present comes from the CJEU and is specifically directed to the SPC Community. It’s the decision in the joint cases C-119/22 and C-149/22. The decision has every potential to bring…
UPDATE on December 24: The Brazilian PTO issued Ordinance Nº 26/2024, introducing critical updates to the Patent Prosecution Highway (PPH) program under Phase V, the so called Global PPH (GPPH) adhesion, set to begin on January 1, 2025. Among these changes is a restriction that excludes patents classified under IPC H04 (Telecommunications) from the PPH…
It has been 1,5 years since the UPC opened its door. The novelty is wearing off as the UPC’s case law takes shape. This is a good moment to reflect a little more on another aspect of the UPC’s operation: the rules of conduct that UPC representatives have to follow. In general, the rules of…
The 2015 landmark decision by the Court of Justice of the European Union (CJEU) in Huawei/ZTE established a balanced framework for licensing standard essential patents (SEPs), striking a compromise between the interests of SEPs holders and implementers. The ruling notoriously clarified when SEP holders can seek injunctions without abusing their dominant market position. It stated…
In case you missed it, here are the main points from the EPO Boards of Appeal Case Law Conference 2024. As ever, this was a really interesting event with lots of high quality presentations. Above all, it is great to hear at first hand what the Board members themselves think of the hot topics at…
Co-authored by Rodrigo Mourao and Rhuan Quintanilha The global momentum behind 5G continues to build up as its adoption accelerates. At the 2024 Mobile World Congress (MWC) in Barcelona, GSMA Intelligence reported that, as of early 2024, “261 operators across 101 countries have launched commercial 5G services. The number of 5G connections worldwide reached 1.6…
This will only be a very short post, but one important new development on the borderline of patent law and antitrust law shall not be left unnoticed on this blog. The European Commission has fined Teva a whopping €462.6 million for abusing its dominant position to delay competition to its blockbuster medicine for the treatment…
We have long meant to write something about the need, or the lack thereof, for adapting the description to amended claims. The announcement in the second preliminary opinion of Technical Board of Appeal (TBA) 3.3.04 in T 56/21, suggesting a referral of this question to the Enlarged Board of Appeal, combined with the sole appellant’s…
Despite the availability of therapeutic options that extend life expectancy, cancer remains one of the leading causes of death worldwide. A key reason for this persistently high mortality rate is the limited effectiveness of conventional treatments in overcoming acquired tumor resistance. Therefore, there is a long felt need for new treatment solutions that continues to…
NO INFRINGEMENT OF RIVAROXABAN DOSAGE FREQUENCY PATENT – DANISH COURT REJECTS BAYER’S APPLICATION FOR PRELIMINARY IN-JUNCTION1. SummaryOn 9 October 2024, the Maritime and Commercial Court rendered its decision not to grant Bayer’s applications for interim measures against four generics — Sandoz, Glenmark, and Stada — based on EP 1 845 961 (“EP 961”).Teva was originally…
